Disease Markers

Disease Markers / 1993 / Article

Open Access

Volume 11 |Article ID 432050 | https://doi.org/10.1155/1993/432050

O. Mansour, T. Motawi, H. Khaled, O. El-Ahmady, "Clinical Value of Thymidine Kinase and Tissue Polypeptide Specific Antigen in Breast Cancer", Disease Markers, vol. 11, Article ID 432050, 7 pages, 1993. https://doi.org/10.1155/1993/432050

Clinical Value of Thymidine Kinase and Tissue Polypeptide Specific Antigen in Breast Cancer

Received27 Apr 1993

Abstract

Thymidine kinase (TK) and tissue polypeptide specific antigen (TPS) were determined in breast cancer (BC) patients (n=83), normal healthy women (n=30) and 18 women with different benign mastopathies. Mean serum levels of TK and TPS in BC patients showed significant increases from their corresponding levels in healthy women and those with benign breast diseases. Diagnostic sensitivity of TK and TPS was 47% and 58% respectively at the selected cut-off values 8 VlL for TK and 110 U/L for TPS (96% specificity). Pre-operati ve serum levels of TK and TPS showed significant correlation with the stage of disease and with other classical prognostic factors; clinical stage, tumour size, lymph node involvement and distant metastasis. Nineteen BC patients were followed-up by serial monthly measurements of TK and TPS (4-10 samples). Both markers seemed to be valuable in monitoring drug efficacy. TK and TPS were able to detect systemic recurrence before clinical diagnosis (average 2 months lead time). TPS was greatly affected by liver diseases.

Copyright © 1993 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views65
Downloads455
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.